{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041422","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.406774+00:00","generated_at":"2026-06-08T02:22:26.824182+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Processa Pharma shareholders approve reverse stock split at ratio up to 1:30","bullets":["Shareholders approved reverse stock split at ratio between 1:5 and 1:30, board to set exact ratio.","Votes: 13,895,377 for, 1,341,351 against, 21,455 abstain; 62% quorum of outstanding shares.","Reverse split must be executed by March 18, 2024, at board's discretion.","Adjournment proposal also approved but not needed since main proposal passed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041422","json":"https://secwatch.observer/filing/0001493152-23-041422.json","markdown":"https://secwatch.observer/filing/0001493152-23-041422.md","text":"https://secwatch.observer/filing/0001493152-23-041422.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223041422/0001493152-23-041422-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223041422/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:22:26.824182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d94aba2464fbe234d2f464471cf150b38fe8150c","claim":"Processa Pharmaceuticals, Inc. shareholders approved grant the Board of Directors discretionary authority to amend the Company’s Fourth Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock, $0.0001 par value per share, at a ratio of not less than 1-for-5 and not more than 1-for-30 at the 2023-11-14 meeting.","evidence_excerpt":"Non-Vote 13,895,377 1,341,351 21,455 - Proposal 2: Adjournment Proposal Shares For Against Abstain Broker","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223041422/0001493152-23-041422-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-14"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}